Zynerba Pharmaceuticals — Investor Presentation (September 2016)
30 slides from Zynerba Pharmaceuticals's investor presentation, Sep 8, 2016
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Zynerba Highlights
Zynerba Highlights 3 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory
Slide 3: Zynerba's Synthetic Cannabinoids
CBD Gel – ZYN002 THC Pro-Drug Patch – ZYN001 Cannabinoid Cannabidiol (CBD) 9-Tetrahydrocannabinol (THC) Delivery Permeation-enhanced gel Transdermal Reservoir patch Development Stage Phase 2 Preclinical Activity Non-psychoactive, decreases neuronal hyperexcitability, multiple mechanisms Psychoactive
Slide 4: Zynerba Expected Milestones through 1H17
Zynerba Expected Milestones through 1H17 5 ZYN002 Timing Phase 1 SRD and MRD Results Completed Phase 2 Adults with Refractory Epilepsy Initiated June 2016 Osteoarthritis Initiated Aug 2016 Fragile X Syndrome 2H16 Phase 2 Top Line Results Adults with Refractory Epilepsy 1H17 Osteoarthritis 1H17 Fragi
Slide 5: CBD Gel – ZYN002
CBD Gel – ZYN002 First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 6 CBD Delivery
Slide 6: CBD Gel – ZYN002 vs. Oral CBD
CBD Gel – ZYN002 vs. Oral CBD 7 Potential Benefits of Transdermal ZYN002 vs. Oral CBD Avoids first-pass metabolism in the liver More consistent, controlled and sustained plasma level Avoids the GI tract Very low incidence of gastrointestinal event Fewer drug-drug interactions Lower incidence of nega
Slide 7: CBD Gel – ZYN002 Avoids Degradation of CBD to THC
CBD Gel – ZYN002 Avoids Degradation of CBD THC 8 in vitro Study ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC CBD degraded to THC in simulated gastric fluid May lead to increased psychoactive effects from THC Study data (Merrick et al.) publishe
Slide 8: CBD Gel ZYN002 – Refractory Epilepsy in Adults
CBD Gel ZYN002 – Refractory Epilepsy in Adults 9 * Data provided by Decision Resources ~ 700,000 adult epilepsy patients are refractory to two or more anti-epileptic drugs in the US* Third-party Phase 3 clinical trial (n=120) with oral botanical CBD to assess safety and efficacy in children with Dra
Slide 9: ZYN002 – Osteoarthritis
ZYN002 – Osteoarthritis 10 ~31 million osteoarthritis sufferers in the US Several pre-clinical studies demonstrate the efficacy of cannabidiol for inflammation and pain in animal models for osteoarthritis/rheumatoid arthritis (OA/RA) In a third-party placebo-controlled study of 58 subjects with rheu
Slide 10: ZYN002 – Osteoarthritis continued
ZYN002 – Osteoarthritis continued 11 Results Significant reductions in: Swelling of knee joints Immune cell infiltration Spontaneous pain rating scores Dose-dependent reduction of pro-inflammatory markers (CD11b/c, CGRP, TNF) in spinal cord and dorsal root ganglia Methods CBD gel was applied for fou
Slide 11: ZYN002 – Fragile X Syndrome
ZYN002 – Fragile X Syndrome 12 Fragile X Syndrome Most common inherited intellectual disability (~71,000 patients in US) Autism spectrum disorder Behavioral and learning challenges Psychiatric and neurological complications FDA granted orphan drug designation for ZYN002 for Fragile X syndrome Caused
Slide 12: CBD Gel – ZYN002 Status
CBD Gel – ZYN002 Status Initiated STOP Phase 2 trial in osteoarthritis in August 2016 Initiated STAR 1 Phase 2 trial in refractory epilepsy in June 2016 Initiating STAR 2 long-term tolerability and efficacy trial in refractory epilepsy in 2H2016 Initiating Phase 2 trial in FXS in 2H2016 Multiple Ris
Slide 13: CBD Gel – ZYN002 Phase 1 Results
Trials 1 day, 7 day, and 14 day trials Subjects 98 healthy volunteers (n= 70 ZYN002; n= 28 placebo) and 22 epilepsy patients (n=16 ZYN002; n=6 placebo) Dose Daily doses levels – 50 to 504 mg CBD in 1%, 2.5% and 4.2% concentrations Safety & Tolerability ZYN002 was safe and well tolerated at all dose
Slide 14: CBD Gel – ZYN002 Phase 2 Clinical Plan
CBD Gel – ZYN002 Phase 2 Clinical Plan 15 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Refractory Epilepsy Adjunctive therapy, double-blind, placebo-controlled 180 patien
Slide 15: ZYN002 – STAR1 Phase 2 Study
ZYN002 – STAR1 Phase 2 Study Initiated June 2016 16 Treatment A: ZYN002 – 195 mg of ZYN002 4.2% CBD gel every 12 hours for 12 weeks Treatment B: ZYN002 – 97.5 mg of ZYN002 4.2% CBD gel every 12 hours for 12 weeks Placebo every 12 hours for 12 weeks 8-week baseline period to assess seizure frequency
Slide 16: ZYN002 – STOP Phase 2 Study
ZYN002 – STOP Phase 2 Study Initiated August 2016 17 Treatment A: ZYN002 – 250 mg of ZYN002 4.2% CBD gel every 12 hours for 12 weeks Treatment B: ZYN002 – 125 mg of ZYN002 4.2% CBD gel every 12 hours for 12 weeks Treatment C: Placebo every 12 hours for 12 weeks 1-week Washout Period; 1-week Baseline
Slide 17: CBD Gel – ZYN002 Initial Market Opportunity
CBD Gel – ZYN002 Initial Market Opportunity 18 Refractory Epilepsy Osteoarthritis Fragile X Syndrome 2012 US Market Size* (# of Patients) 2.2 million 31 million 71,000 Orphan drug designation granted** 2012 EU and Japan* Market Size (# of Patients) 3.1 million 53 million 88,542 * Except for Fragile
Slide 18: THC Pro-Drug Patch – ZYN001
THC Pro-Drug Patch – ZYN001 19 Patent-protected synthetic D-glyceric acid ester-9-tetrahydrocannabinol in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a no
Slide 19: Why a Patch?
Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 20 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, contro
Slide 20: ZYN001 – Fibromyalgia
~ 5.6 million patients suffer from Fibromyalgia in the US* CB1 agonists Have an analgesic effect in chronic pain models Act at many sites along pain transmission pathways Nabilone (THC analogue) in patients with fibromyalgia Third-party 4-week, randomized, double-blind, placebo-controlled trial (N=4
Slide 21: ZYN001 – Peripheral Neuropathic Pain
~ 14 million patients suffer from Peripheral Neuropathic Pain in the US* Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN received low (1% THC), medium
Slide 22: THC Pro-Drug Patch – ZYN001 Status
THC Pro-Drug Patch – ZYN001 Status FDA pre-IND meeting completed August 2013 in vitro and in vivo studies Effective skin permeation with sustained delivery Non-mutagenic and non-genotoxic Safety pharmacology GLP studies Profile similar to THC GLP toxicology studies ongoing Expected Phase 1 to be ini
Slide 23: THC Pro-Drug Patch – ZYN001 Preliminary Phase 1 Clinical Plan
THC Pro-Drug Patch – ZYN001 Preliminary Phase 1 Clinical Plan 24 Trial Patients Dosing PD Evaluations Timing Single Rising Dose Trial in Normal Subjects Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 patients with fibromyalgia Single dose Cognition and attention (Tr
Slide 24: THC Pro-Drug Patch – ZYN001 Preliminary Phase 2 Clinical Plan
THC Pro-Drug Patch – ZYN001 Preliminary Phase 2 Clinical Plan 25 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 1
Slide 25: THC Pro-Drug Patch – ZYN001 Initial Market Opportunity
THC Pro-Drug Patch – ZYN001 Initial Market Opportunity 26 Fibromyalgia Peripheral Neuropathic Pain 2012 US Market Size* (# of Patients) 5.6 million 14.0 million 2012 EU and Japan Market Size* (# of Patients) 10.8 million 20.3 million Data provided by Decision Resources.
Slide 26: Scientific Advisors
Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M
Slide 27: Zynerba Highlights
Zynerba Highlights 29 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory
Slide 28: Investor Relations
Investor Relations 30 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Canaccord Genuity: Arlinda Lee, PhD Oppenheimer: Rohit Vanjani Roth: Michael Higgins * Note: Any opinions, estimates or forecasts regarding Zynerba Pharmaceuticals, Inc.’s performanc
Slide 29: September 2016
September 2016 A clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs
Slide 30: A clini ialty pharmaceutical
A clini ialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs September 2016
Zynerba Pharmaceuticals — Investor Presentation (September 2016) on 6ix